Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies

Introduction: allogeneic hematopoietic stem cell transplantation is a potentially curative treatment modality for hematological malignancies. we evaluated the outcome of patients suffering from hematological malignancies, including acute leukemias, chronic myeloid leukemia and myelodysplastic syndrome after allogeneic transplantation. methods: all patients having hematological malignancies with hla identical sibling donors who underwent allogeneic transplantation were included. pre-transplant workup consisted of complete blood counts, evaluation of liver, kidneys, lungs, infectious profile, chest x-ray, paranasal sinus roentgenograms and dental review. donors were given g-csf at a dose of 5-10 μg/kg/twice daily for five days prior to harvest. the conditioning regimens included cyclophosphamide, busulfan and total body irradiation. results: a total of 41 allogeneic transplants were performed for hematological malignancies from april 2004 to december 2012. there were 31 males and 10 females. median age ± sd was 28 ± 11.7 years (range 8 – 54 years). a mean of 7.7x108±1.5 mononuclear cells/kg were infused (range:6.2-9.2x108/kg). the median time to white cell recovery was 19±4 days (range:15-23 days). transplant related mortality was 19.5%. the median overall survival was 53.6 months. overall survival at a median follow up of 37 months was 67%. conclusion: allogeneic stem cell transplantation is an effective treatment option in patients with hematological malignancies. our outcomes are comparable with results from neighboring countries as well as the western world.